Zydus Lifesciences Ltd — earnings calls

Zydus Lifesciences reported consolidated revenue of ₹271.5 billion for FY26, up 17% year-on-year, with EBITDA margin at 31.2% and net profit adjusted for exceptional items at ₹54.6 billion, up 15%. Q4 FY26 revenue was ₹75.9 billion, up 16% year-on-year, with EBITDA margin of 33.7% and adjusted net profit of ₹15.9 billion. Management discussed growth across US formulations, India branded formulations, international markets, consumer wellness and medical devices, along with the proposed acquisition of Assertio Holdings and other pipeline updates.